Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE6D | O43924 | 1/20 | 0.40 |
| ▸ | PDE8A | O60658 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 1/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | PDE6A | P16499 | 1/20 | 0.40 |
| ▸ | PDE6G | P18545 | 1/20 | 0.40 |
| ▸ | PDE6B | P35913 | 1/20 | 0.40 |
| ▸ | PDE6C | P51160 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14450075 | 0.77 | TNKS (0.59) | TNKSL3MBTL1PDE4APDE3APDE2A | |
| SCHEMBL14450074 | 0.77 | TNKS (0.52) | TNKSL3MBTL1PDE4APDE3APDE2A | |
| SCHEMBL7338405 | 0.76 | TNKS (1.00) | TNKSL3MBTL1PDE4APDE3APDE2A | |
| SCHEMBL7330087 | 0.74 | TNKS (0.63) | TNKSL3MBTL1PDE4APDE3APDE2A | |
| SCHEMBL7339375 | 0.72 | TNKS (0.71) | TNKSADORA3ADORA1 | |
| SCHEMBL25096399 | 0.72 | ADORA3 (0.43) | TNKSADORA3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL7332529 | 0.71 | TNKS (0.74) | TNKSPDE4APDE3APDE2APDE6D | |
| SCHEMBL21103831 | 0.70 | POLB (0.39) | TNKSADORA3GRIN2DGRIN3BGRIA1 | |
| SCHEMBL7337736 | 0.70 | TNKS (0.73) | TNKSPDE3APDE3BADORA3PARP1 | |
| SCHEMBL7334632 | 0.69 | TNKS (0.74) | TNKSPDE4APDE3APDE2APDE6D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| EP-2567960-A2 | Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis | Biofocus DPI Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| EP-2567960-A2 | Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis | Biofocus DPI Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| EP-2193131-B1 | IMIDAZO[1,2-A]PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LTD (GB) | 2013-01-30 | — | — | EP | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| EP-2193131-A2 | IMIDAZO[1,2-A]PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | Biofocus DPI Limited (GB) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009024585-A2 | IMIDAZO [1,2-A] PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024585-A2 | IMIDAZO [1,2-A] PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
| US-20070155751-A1 | NOVEL IMIDAZOPYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155751-A1 | NOVEL IMIDAZOPYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-7186740-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186740-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | TNKS 4573/4885L3MBTL1 4582/4885PDE4A 2028/4885 |
| US-20070155751-A1 | NOVEL IMIDAZOPYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS | CDK2, CDKN1A, CDK1 | TNKS 254/4885L3MBTL1 3942/4885PDE4A 1311/4885 |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | TNKS, TANK, TBKBP1 | TNKS 1/4885L3MBTL1 771/4885PDE4A 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.